Affibody-mediated controlled release of fibroblast growth factor 2

Chiara Bostock; Carter J. Teal; Mickael Dang; Alex W. Golinski; Benjamin J. Hackel; Molly S. Shoichet

doi:10.1016/j.jconrel.2022.09.004

Affibody-mediated controlled release of fibroblast growth factor 2

Chiara Bostock, Carter J. Teal, Mickael Dang, Alex W. Golinski, Benjamin J. Hackel, Molly S. Shoichet

Chemical Engineering and Materials Science

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Protein therapeutics possess high target affinity and specificity, yet short residence times, which limit their broad utility. To overcome this challenge, we used affinity interactions to modulate protein release from a hydrogel delivery vehicle thereby prolonging therapeutic availability. Specifically, we designed an affibody-modified hyaluronan (HA)-based hydrogel as a delivery platform for fibroblast growth factor 2 (FGF2), a neuroprotective and neuroregenerative factor in the central nervous system (CNS). We identified a highly specific affibody binding partner with moderate affinity for FGF2 using yeast surface display and flow cytometry-based screening. Importantly, we demonstrated controlled release of bioactive FGF2 from the hydrogel by varying the ratio of affibody to protein and showed increased thermal stability of FGF2 in the presence of affibody. This versatile delivery platform will allow the distinct, simultaneous release of multiple proteins based on specific affinity interactions.

Original language	English (US)
Pages (from-to)	815-828
Number of pages	14
Journal	Journal of Controlled Release
Volume	350
DOIs	https://doi.org/10.1016/j.jconrel.2022.09.004
State	Published - Oct 2022

Bibliographical note

Funding Information:
Funding for this work was provided in part by the Canadian Institutes of Health Research (Foundation Grant to MSS), Natural Sciences and Engineering Research Council of Canada (Discovery and Herzberg to MSS; PGS-D to CT; CREATE-PROMOTE to MD), Canada First Research Excellence Fund via Medicine by Design (to MSS), Vision Science Research Program (to CT), Ontario Government (OGS to CB), Connaught International Scholarship (to MD), and U.S. National Science Foundation Graduate Research Fellowship (to AG).

Publisher Copyright:
© 2022 Elsevier B.V.

Keywords

Affinity interactions
Controlled release
Fibroblast growth factor 2
Hyaluronan
Hydrogel
Protein delivery

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

Access

10.1016/j.jconrel.2022.09.004

OpenUrl availability

Full text

Cite this

@article{fad1ac9dfe2d42aca4d4ed1bb7b5c054,

title = "Affibody-mediated controlled release of fibroblast growth factor 2",

abstract = "Protein therapeutics possess high target affinity and specificity, yet short residence times, which limit their broad utility. To overcome this challenge, we used affinity interactions to modulate protein release from a hydrogel delivery vehicle thereby prolonging therapeutic availability. Specifically, we designed an affibody-modified hyaluronan (HA)-based hydrogel as a delivery platform for fibroblast growth factor 2 (FGF2), a neuroprotective and neuroregenerative factor in the central nervous system (CNS). We identified a highly specific affibody binding partner with moderate affinity for FGF2 using yeast surface display and flow cytometry-based screening. Importantly, we demonstrated controlled release of bioactive FGF2 from the hydrogel by varying the ratio of affibody to protein and showed increased thermal stability of FGF2 in the presence of affibody. This versatile delivery platform will allow the distinct, simultaneous release of multiple proteins based on specific affinity interactions.",

keywords = "Affinity interactions, Controlled release, Fibroblast growth factor 2, Hyaluronan, Hydrogel, Protein delivery",

author = "Chiara Bostock and Teal, {Carter J.} and Mickael Dang and Golinski, {Alex W.} and Hackel, {Benjamin J.} and Shoichet, {Molly S.}",

note = "Funding Information: Funding for this work was provided in part by the Canadian Institutes of Health Research (Foundation Grant to MSS), Natural Sciences and Engineering Research Council of Canada (Discovery and Herzberg to MSS; PGS-D to CT; CREATE-PROMOTE to MD), Canada First Research Excellence Fund via Medicine by Design (to MSS), Vision Science Research Program (to CT), Ontario Government (OGS to CB), Connaught International Scholarship (to MD), and U.S. National Science Foundation Graduate Research Fellowship (to AG). Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2022",

month = oct,

doi = "10.1016/j.jconrel.2022.09.004",

language = "English (US)",

volume = "350",

pages = "815--828",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier",

}

TY - JOUR

T1 - Affibody-mediated controlled release of fibroblast growth factor 2

AU - Bostock, Chiara

AU - Teal, Carter J.

AU - Dang, Mickael

AU - Golinski, Alex W.

AU - Hackel, Benjamin J.

AU - Shoichet, Molly S.

N1 - Funding Information: Funding for this work was provided in part by the Canadian Institutes of Health Research (Foundation Grant to MSS), Natural Sciences and Engineering Research Council of Canada (Discovery and Herzberg to MSS; PGS-D to CT; CREATE-PROMOTE to MD), Canada First Research Excellence Fund via Medicine by Design (to MSS), Vision Science Research Program (to CT), Ontario Government (OGS to CB), Connaught International Scholarship (to MD), and U.S. National Science Foundation Graduate Research Fellowship (to AG). Publisher Copyright: © 2022 Elsevier B.V.

PY - 2022/10

Y1 - 2022/10

N2 - Protein therapeutics possess high target affinity and specificity, yet short residence times, which limit their broad utility. To overcome this challenge, we used affinity interactions to modulate protein release from a hydrogel delivery vehicle thereby prolonging therapeutic availability. Specifically, we designed an affibody-modified hyaluronan (HA)-based hydrogel as a delivery platform for fibroblast growth factor 2 (FGF2), a neuroprotective and neuroregenerative factor in the central nervous system (CNS). We identified a highly specific affibody binding partner with moderate affinity for FGF2 using yeast surface display and flow cytometry-based screening. Importantly, we demonstrated controlled release of bioactive FGF2 from the hydrogel by varying the ratio of affibody to protein and showed increased thermal stability of FGF2 in the presence of affibody. This versatile delivery platform will allow the distinct, simultaneous release of multiple proteins based on specific affinity interactions.

AB - Protein therapeutics possess high target affinity and specificity, yet short residence times, which limit their broad utility. To overcome this challenge, we used affinity interactions to modulate protein release from a hydrogel delivery vehicle thereby prolonging therapeutic availability. Specifically, we designed an affibody-modified hyaluronan (HA)-based hydrogel as a delivery platform for fibroblast growth factor 2 (FGF2), a neuroprotective and neuroregenerative factor in the central nervous system (CNS). We identified a highly specific affibody binding partner with moderate affinity for FGF2 using yeast surface display and flow cytometry-based screening. Importantly, we demonstrated controlled release of bioactive FGF2 from the hydrogel by varying the ratio of affibody to protein and showed increased thermal stability of FGF2 in the presence of affibody. This versatile delivery platform will allow the distinct, simultaneous release of multiple proteins based on specific affinity interactions.

KW - Affinity interactions

KW - Controlled release

KW - Fibroblast growth factor 2

KW - Hyaluronan

KW - Hydrogel

KW - Protein delivery

UR - http://www.scopus.com/inward/record.url?scp=85137809972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137809972&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2022.09.004

DO - 10.1016/j.jconrel.2022.09.004

M3 - Article

C2 - 36087800

AN - SCOPUS:85137809972

SN - 0168-3659

VL - 350

SP - 815

EP - 828

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Affibody-mediated controlled release of fibroblast growth factor 2

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this